← brief for 2026-10-12 · Slowing decline

Comparative Cardiorenal Efficacy and Safety of SGLT2 Inhibitors and Finerenone in Chronic Kidney Disease With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

This review compared two kidney drugs, SGLT2 inhibitors and finerenone. It used data from 10 trials. Both drugs slowed kidney decline in people with type 2 diabetes. This is a strong review of existing trial data.

Who did this work

Alghzawi F · Alghzawi Y · Alhassan L · Kiyyam R

Source

Article · PubMed, the drug frontier · 2026 Oct 12
https://pubmed.ncbi.nlm.nih.gov/42864264/